REFERENCE
Conroy T, Hebbar M, Bennouna J, Ducreux M, Ychou M, Llédo G, Adenis A, Faroux R, Rebischung C, Kockler L, Douillard JY.Quality of life of patients with metastatic colorectal cancer receiving either XELOX or FOLFOX-6 regimen: a randomized phase III study. 11th World Congress on Gastrointestinal Cancer: 13 abstr. O-0021, May-Jun 2009. Available from: URL: http://www.worldgicancer.com
Rights and permissions
About this article
Cite this article
The XELOX regime is more convenient and saves time for patients with colorectal cancer. Pharmacoecon. Outcomes News 582, 10 (2009). https://doi.org/10.2165/00151234-200905820-00023
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-200905820-00023